The 2024 Lymphoma Research Foundation Workshop developed consensus recommendations for the selection and sequencing of therapies for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in the US. These recommendations aim to bridge the gap between existing guidelines and real-world practices, addressing the challenges posed by the shift from traditional chemoimmunotherapy to targeted therapies amidst a lack of randomized clinical trial data.

The study identifies the CAT rs1001179 single nucleotide polymorphism (SNP) as a potential prognostic factor in chronic lymphocytic leukemia (CLL), indicating that the TT genotype is associated with a shorter time-to-first-treatment (TTFT) and faster clinical progression. This finding suggests that the SNP could enhance risk stratification and inform personalized treatment strategies for CLL patients.

This study examines the characteristics, treatment patterns, and outcomes of 1,283 patients with chronic lymphocytic leukemia (CLL) in the U.S. who received two or more lines of therapy between 2014 and 2022. It highlights a decrease in chemoimmunotherapy use and an increase in targeted therapies, while noting significant mortality rates and ongoing unmet needs for patients undergoing late-line treatments.

This study evaluates the effectiveness of diagnostic next generation sequencing (NGS) for detecting the MYD88 L265P mutation in lymphoplasmacytic lymphoma (LPL) compared to droplet digital PCR (ddPCR). The findings indicate that NGS can be a sensitive and reliable method for detecting this mutation, achieving comparable detection rates to ddPCR with appropriate assessment parameters.

This study investigates the frequency and correlation of laboratory findings, including peripheral blood smear and bone marrow analysis, in patients with chronic lymphocytic leukemia (CLL). It evaluates demographic and laboratory factors in 161 CLL patients, finding significant relationships between bone marrow iron storage and atypical lymphocyte percentages, highlighting the importance of these diagnostic techniques for timely diagnosis and prognosis.

This multicenter study evaluates the ability of next-generation sequencing (NGS) methods to detect low-variant allelic frequency (VAF) TP53 mutations in chronic lymphocytic leukemia (CLL) and their impact on patient survival. The findings indicate that while NGS can reliably identify low-VAF variants, these mutations are associated with significantly shorter time to second treatment and overall survival in patients not treated with targeted therapies. The study underscores the importance of validating NGS methods and understanding their clinical implications.

This study evaluates the significance of serum interleukin-22 levels in patients with chronic lymphocytic leukemia (CLL) and its relationship with disease characteristics. The findings indicate that IL-22 levels are significantly higher in CLL patients compared to healthy controls and correlate positively with ZAP-70 expression, suggesting that IL-22 could serve as a diagnostic and prognostic marker in CLL management.